MEMORANDUM

TO: Local Health Departments and Regional Offices of the Illinois Department of Public Health, Hospital Emergency Departments, Infectious Disease Physicians, Infection Control Professionals

FROM: Illinois Department of Public Health
Communicable Disease Control Section

DATE: February 11, 2015

SUBJECT: Measles Guidance for Clinicians

Current Situation
Ten cases of measles have been confirmed in Illinois this year. All cases reside in or are linked to a daycare in suburban Cook County. Onsets range from January 16 to February 7, 2015. Contacts to cases are being identified and actively monitored and additional cases may be identified. Since December 2014, measles infections have also been detected in several states throughout the country. The majority are associated with an ongoing measles outbreak linked to an amusement park in California. Currently, there is no evidence to suggest Illinois cases are linked to the ongoing outbreak in California. Healthcare providers should be aware of the potential for measles cases at their facility and the proper measles testing and isolation procedures.

Measles
Measles is a highly contagious respiratory disease caused by a virus, transmitted by direct contact with infectious droplets or by airborne spread when an infected person breathes, coughs, or sneezes. Measles virus can remain infectious on surfaces and in the air for up to two hours after an infected person leaves an area. Typically, measles starts with a fever, runny nose, cough, red eyes, and sore throat, and is followed by a rash that spreads all over the body. The symptoms of measles generally appear 7 to 14 days after a person is exposed; however, the incubation period ranges from 7 to 21 days. Patients are considered to be contagious from 4 days before to 4 days after the rash appears.

Consider measles in any patient with febrile rash illness and clinically compatible measles symptoms, who has recently traveled abroad, was born after 1957 and has not been vaccinated, or who has had contact with someone with a febrile rash illness. Immunocompromised patients may not exhibit rash or may exhibit an atypical rash. Photos of a patient’s rash may be helpful in determining if it is characteristic of measles. Photos of measles and persons with measles can be found at http://www.cdc.gov/measles/about/photos.html.
What should clinicians do?

- Display signage in waiting rooms asking that all patients that come in with a fever and a rash alert the clinic staff immediately.

- Mask suspect measles patients immediately. If a surgical mask cannot be tolerated, other practical means of containment should be implemented (e.g., place a blanket loosely over the heads of infants and young children suspected to have measles when they are in common areas, such as hallways, as they are being placed in a room).

- Do not allow suspect measles patients to remain in the waiting area or other common areas; isolate them immediately in a negative pressure room if one is available. If such a room is not available, place patient in a private room with the door closed.

- For more infection prevention and control information see attached guidance document.

- Ask any patient with a febrile rash illness the following questions to assess risk:
  - Have you travelled outside of the country or has anyone visited you from outside the country?
  - Have you travelled anywhere in the United States? *(ask about domestic venues frequented by international travelers)*
  - Have you been exposed to anyone with measles in your community?
  - Have you received MMR vaccine before? *(for patients 6 months and older)*

- Notify your local health department immediately of any suspected case of measles. Measles testing can be performed at the Illinois Department of Public Health Laboratories in Springfield and Chicago, for highly suspected cases of measles. Your health department will arrange testing and advise on specimen collection and transport.

- Counsel patients suspected to have measles to remain at home with no visitors until testing is complete and they have been cleared by their physician. Note, patients who have had contact with a confirmed case and have symptoms consistent with measles should remain isolated regardless of lab results.

- Make note of the staff and other patients who were in the area during the time the suspect measles patient was in the facility and for two hours after the suspected case left the clinic. If measles is confirmed in the suspect case, exposed people will need to be assessed for measles immunity.

**Reporting Recommendations**
Clinicians should report suspected cases of measles to their local health department immediately by phone. The local health department should notify IDPH by phone as soon as possible, within 24 hours.

**Testing Recommendations**
Measles RT-PCR is the preferred method of testing for measles. It can be performed at the IDPH laboratory on respiratory specimens only and should be used in conjunction with serology testing at a commercial lab. Preauthorization from your local health department is required before submitting any specimen to IDPH for measles RT-PCR testing. Preferred specimens for measles RT-PCR testing include nasopharyngeal washes and nasopharyngeal or throat Dacron swabs collected in viral transport medium and stored at 4°C. Attempt to obtain the specimen as
soon as possible after the onset of the rash. Samples collected more than five days after rash onset have much lower chances of successful viral detection. Specimen collection and submission information can be found at http://www.dph.illinois.gov/sites/default/files/Manual_of_Services_OHP_LABS.pdf

Post-exposure Prophylaxis
People exposed to measles who cannot readily show that they have evidence of immunity** against measles should be offered post-exposure prophylaxis (PEP). MMR vaccine, if administered within 72 hours of initial measles exposure, or immunoglobulin (IG), if administered within six days of exposure, may provide some protection or modify the clinical course of disease.

MMR vaccine as post-exposure prophylaxis
If MMR vaccine is not administered within 72 hours of exposures as PEP, MMR should still be offered at any interval following exposure to the disease in order to offer protection from future exposures. People who receive MMR vaccine or IG as PEP should be monitored for signs and symptoms consistent with measles for at least one incubation period.

Except in healthcare and childcare settings, unvaccinated people who receive their first dose of MMR vaccine within 72 hours after exposure may return school or work. In childcare settings, unvaccinated people may not return to the daycare for 21 days after exposure, unless otherwise instructed by their local health department. Children vaccinated before their first birthday should be revaccinated when they are 12-15 months old and again when they are 4-6 years old, or at least 28 days after the first dose that was received after 12 months.

Immune Globulin (IG) as Post-Exposure Prophylaxis
People who are at risk for severe illness and complications from measles, such as infants younger than 12 months of age, pregnant women without evidence of measles immunity, and people with severely compromised immune systems, should receive IG. Intramuscular IG (IGIM) should be given to all infants younger than 12 months of age who have been exposed to measles. For infants aged 6 through 11 months, MMR vaccine can be given in place of IG, if administered within 72 hours of exposure. Because pregnant women might be at higher risk for severe measles and complications, intravenous IG (IGIV) should be administered to pregnant women without evidence of measles immunity who have been exposed to measles. People with severely compromised immune systems who are exposed to measles should receive IGIV regardless of immunologic or vaccination status because they might not be protected by MMR vaccine.

Please see attached immune globulin guidelines from IDPH for additional details.

Post-exposure Prophylaxis for Healthcare Personnel
If a healthcare provider without evidence of immunity is exposed to measles, MMR vaccine should be given within 72 hours, or IG should be given within 6 days when available. Exclude healthcare personnel without evidence of immunity from duty from day 5 after first exposure to day 21 after last exposure, regardless of post-exposure prophylaxis.

Healthcare Personnel Vaccination Recommendations
All persons who work in health-care facilities should have presumptive evidence of immunity to measles. This information should be documented and readily available at the work location.
Presumptive evidence of immunity to measles for persons who work in health-care facilities includes any of the following:

- Written documentation of vaccination with 2 doses of live measles or MMR vaccine administered at least 28 days apart
- Laboratory evidence of immunity (titer),
- Laboratory confirmation of disease, or
- Birth before 1957*

*Although birth before 1957 is considered as presumptive evidence of immunity, for unvaccinated HCP born before 1957 that lack laboratory evidence of measles immunity or laboratory confirmation of disease, health care facilities should consider vaccinating personnel with two doses of MMR vaccine at the appropriate interval.

Measles Vaccination
The best prevention for measles is vaccination; current CDC and ACIP guidelines for vaccination are as follows:

1. Administer a 2-dose series of MMR vaccine at ages 12-15 months and 4-6 years. The second dose may be administered before age 4 years, provided at least 28 days have elapsed after the first dose.
2. For those who travel abroad, CDC recommends that all U.S. residents older than 6 months be protected from measles and receive MMR vaccine, if needed, prior to departure.
   a. Infants 6 through 11 months old should receive 1 dose of MMR vaccine before departure.
   b. Children 12 months of age or older should have documentation of 2 doses of MMR vaccine (separated by at least 28 days).
   c. Teenagers and adults without evidence of measles immunity, should have documentation of appropriately spaced doses of MMR vaccine.
3. Infants who receive a dose of MMR vaccine before their first birthday should receive 2 more doses of MMR vaccine, the first of which should be administered when the child is 12 through 15 months of age and the second at least 28 days later.

Additional Resources
For more information, including guidelines for patient evaluation, diagnosis and management, visit: [http://www.cdc.gov/measles/hcp/](http://www.cdc.gov/measles/hcp/)


For more information on healthcare personnel vaccination recommendations, visit: [http://www.cdc.gov/mmwr/pdf/rr/rr6007.pdf](http://www.cdc.gov/mmwr/pdf/rr/rr6007.pdf)

For more information on measles post-exposure prophylaxis, visit: [http://www.cdc.gov/measles/hcp/](http://www.cdc.gov/measles/hcp/)
Measles Health Alert

Measles outbreaks have originated from returning international travelers or visiting domestic venues frequented by international travelers, and limited community transmission can occur. Measles is highly contagious. Please protect patients, visitors, and staff!

Keep an eye out for measles symptoms:

Suspect measles in patients with:
- fever and rash, and
- history of exposure to a case, or
- history of international travel, contact with international visitors or visiting venues frequented by international visitors in the past 3 weeks, or
- any patient with clinically compatible symptoms

Note: A history of 2 doses of MMR vaccine does not exclude a measles diagnosis.

Prodrome
- Mild to moderate fever
- Cough
- Coryza
- Conjunctivitis

Rash onset
- Fever spikes, often as high as 104º to 105º F
- Red, maculopapular rash that may become confluent—typically starts at hairline, then face, and spreads rapidly down body
- Koplik’s spots (tiny blue/white spots on the bright red background of the buccal mucosa) may be present

Act immediately if you suspect measles:

- Implement airborne infection control precautions immediately, mask and isolate patient—negative pressure room, if available.
- Permit only staff immune to measles to be near the patient.
- Notify local health department immediately.
- Expedite measles serologic (IgM and IgG) at a commercial lab and PCR testing through the IDPH lab.
- Safeguard other facilities: assure airborne infection control precautions before referring patients.
- Do not use any regular exam room for at least 2 hours after a suspected measles patient has left the room.
IMMUNE GLOBULIN (IG) FOR THE PROPHYLAXIS OF MEASLES
Updated February 2015

1. BACKGROUND

If administered within 6 days of exposure, IG can prevent or modify measles in persons who are nonimmune. IG is not indicated for persons who have received 1 dose of measles-containing vaccine at age ≥12 months, unless they are severely immunocompromised (see below). IG should not be used to control measles outbreaks, but rather to reduce the risk for infection and complications in the person receiving it. IG has not been shown to prevent rubella or mumps infection after exposure and is not recommended for that purpose.

Any nonimmune person exposed to measles who received IG should subsequently receive MMR vaccine, which should be administered no earlier than 6 months after IGIM administration or 8 months after IGIV administration, provided the person is then aged ≥12 months and the vaccine is not otherwise contraindicated.

**Recommended Dose of Immune Globulin for Postexposure Prophylaxis**

The recommended dose of IG administered intramuscularly (IGIM) is 0.5 mL/kg of body weight (maximum dose = 15 mL) and the recommended dose of IG given intravenously (IGIV) is 400 mg/kg.

**Recommendations for Use of Immune Globulin for Postexposure Prophylaxis**

The following patient groups are at risk for severe disease and complications from measles and should receive IG: infants aged <12 months, pregnant women without evidence of measles immunity, and severely immunocompromised persons. IGIM can be administered to other persons who do not have evidence of measles immunity, but priority should be given to persons exposed in settings with intense, prolonged, close contact (e.g., household, daycare, and classroom). For exposed persons without evidence of measles immunity, a rapid IgG antibody test can be used to inform immune status, provided that administration of IG is not delayed.

**Infants aged <12 months.** Because infants are at higher risk for severe measles and complications, and infants are susceptible to measles if mothers are nonimmune or their maternal antibodies to measles have waned (337), IGIM should be administered to all infants aged <12 months who have been exposed to measles. Note: for infants aged 6 through 11 months, MMR vaccine can be administered in place of IG if administered within 72 hours of exposure.
**Pregnant women without evidence of measles immunity.** Because pregnant women might be at higher risk for severe measles and complications (20), IGIV should be administered to pregnant women without evidence of measles immunity who have been exposed to measles. IGIV is recommended to administer doses high enough to achieve estimated protective levels of measles antibody titers.

**Immunocompromised patients.** Severely immunocompromised patients who are exposed to measles should receive IGIV prophylaxis regardless of immunologic or vaccination status because they might not be protected by the vaccine. Severely immunocompromised patients include: patients with severe primary immunodeficiency; patients who have received a bone marrow transplant until at least 12 months after finishing all immunosuppressive treatment, or longer in patients who have developed graft-versus-host disease; patients on treatment for ALL within and until at least 6 months after completion of immunosuppressive chemotherapy; and patients with a diagnosis of AIDS or HIV-infected persons with severe immunosuppression defined as CD4 percent <15% (all ages) or CD4 count <200 lymphocytes/mm3 (aged >5 years) and those who have not received MMR vaccine since receiving effective ART. Some experts include HIV-infected persons who lack recent confirmation of immunologic status or measles immunity.

For persons already receiving IGIV therapy, administration of at least 400 mg/kg body weight within 3 weeks before measles exposure should be sufficient to prevent measles infection. For patients receiving subcutaneous immune globulin (IGSC) therapy, administration of at least 200 mg/kg body weight for 2 consecutive weeks before measles exposure should be sufficient.

**2. ORDERING IMMUNOGLOBULIN:**

1. Screen for contraindications.
2. Provide product information, answering questions.
3. Give immune globulin (IG) intramuscularly (IM) to children and adults with a 1 to 2 inch needle, depending on recipient’s weight.
4. Select a large muscle mass that can support the administration of a large volume of IG.
   a. For children <3 years of age, administer IG into the vastus lateralis (outer thigh) muscle with a 7/8 to-1 inch needle. For certain very small infants a 5/8 inch needle may be adequate.
   b. For persons ≥3 years of age, administer IG into the ventrogluteal or dorsogluteal muscle with a 1-2 inch needle.
   c. For adults with sufficient deltoid muscle mass, the deltoid muscle may be used.
5. Use formulation and dosage according to recipient’s weight. (Section 3.)
6. Do not administer more than 3 ml of IG per injection site in children or more than 5 ml of IG per injection site in adults.
7. IG and measles vaccine should not be given at the same time. See attached for
information about suggested intervals between IG and measles vaccine.

10. IG can be administered simultaneously with, or at any interval before or after, any inactivated vaccine.

Note: Measles vaccine is the biologic of choice if given within 72 hours of exposure. For persons in whom vaccine is contraindicated or more than 72 hours passed, and they are still within 6 days of exposure, immune globulin should be used.

3. IMMUNE GLOBULIN DOSE SCHEDULE FOR MEASLES EXPOSURE\textsuperscript{1,2,3,4}

<table>
<thead>
<tr>
<th>Indications</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard immunocompetent Contact &gt; 12 months</td>
<td>0.5 ml/kg (max dose 15mL) IM</td>
</tr>
<tr>
<td>Infants &lt;12 months\textsuperscript{5}</td>
<td>0.5 ml/kg IM (max dose = 15mL)</td>
</tr>
<tr>
<td>Pregnant women without evidence of immunity</td>
<td>400 mg/kg IV (intravenously)</td>
</tr>
<tr>
<td>Severely immunocompromised persons\textsuperscript{6}</td>
<td>400 mg/kg IV (intravenously) IVIG</td>
</tr>
</tbody>
</table>

\textsuperscript{1} IG should be administered at room temperature and within 6 days of exposure.

\textsuperscript{2} IG should only be administered to susceptible children and adults. Note that most infants (>90%) in the United States still have some protection from circulating maternal antibodies through their 5th month of life. (An exception is infants <5 months whose mothers develop measles; indicating that she has little or no antibody against measles.) \textbf{Nevertheless, IGIM should be administered to all infants aged <12 months who have been exposed to measles.} For infants aged 6 through 11 months, MMR vaccine can be administered in place of IG if administered within 72 hours of exposure.

\textsuperscript{3} IGIM can be given to any person who lacks evidence of measles immunity, but priority should be given to persons exposed in settings with intense, prolonged, close contact (e.g., household, childcare, classroom, etc.).

\textsuperscript{4} The maximum dose is 15 ml intramuscularly for all persons.

\textsuperscript{5} \textbf{Note that MMR vaccines can be given to infants' age 6–11 months for international travel.}

\textsuperscript{6} Severely immunocompromised patients include patients with severe primary immunodeficiency; patients who have received a bone marrow or stem cell transplant until at least 12 months after finishing all immunosuppressive treatment, or longer where the patient has developed graft-versus-host disease; patients on treatment for Acute Lymphocytic Leukemia; until at least six months after completion of immunosuppressive chemotherapy; and patients with a diagnosis of AIDS or HIV-infected persons with CD4 percent <15% (all ages) or CD4 <200 lymphocytes /mm3 (age >5 years) and those who have not received MMR vaccine since receiving effective anti-retroviral therapy; some experts would include HIV infected persons who lack recent confirmation of immunologic status or measles immunity.
4. CONTRAINDICATIONS:
   1. IG should not be given to people with immunoglobulin A (IgA) deficiency. Persons with IgA deficiencies have the potential for developing antibodies to IgA and therefore could experience an anaphylactic reaction when IG is administered.
   2. IG should not be administered to persons with severe thrombocytopenia or any coagulating disorder that would contraindicate intramuscular injections.
   3. History of anaphylactic reaction to a previous dose of IG.

5. PRECAUTIONS:
   1. Pregnancy: It is unknown whether IG can cause fetal harm when administered to a pregnant woman or if it could affect reproduction. (Pregnancy Category C)
   2. Careful administration in persons reporting a history of systemic allergic reaction following the administration of IG.

6. SIDE EFFECTS AND ADVERSE REACTIONS:

<table>
<thead>
<tr>
<th>Event</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenderness, pain, or soreness at injection site. Usually resolves within 24 hours.</td>
<td>Common</td>
</tr>
</tbody>
</table>

7. OTHER CONSIDERATIONS:
   A. IG may interfere with the response to live, attenuated vaccines (e.g. MMR, varicella) when the vaccines are administered individually or as a combined vaccine. Delay administration of live attenuated vaccines for 5 months after the administration of IG. (See attached ACIP recommendations.)
   B. Ideally, IG should not be administered within 2 weeks following the administration of MMR or for 3 weeks following varicella vaccine. Should this occur, the individual should be revaccinated, but no sooner than 5 months after IG administration.
   C. For individuals currently on immune globulin intravenous therapy (IGIV), the dose of 100 to 400 mg/kg should be sufficient prophylaxis for exposures occurring in the three weeks following treatment.
   D. In the event of a community outbreak, the age at which the first measles vaccine is recommended may be as low as 6 months. These infants, however, will still need a dose of MMR at or after 12 months of age and a third dose at school entry, 4 to 6 years of age.
VII. REFERENCES:

1. CDC. ACIP Recommendations for prevention of measles, rubella, congenital rubella syndrome (CRS), and mumps, 2013. Available at http://www.cdc.gov/mmwr/pdf/rr/rr6204.pdf


## Recommended intervals between administration of immune globulin preparations and measles- or varicella-containing vaccine

<table>
<thead>
<tr>
<th>Product / Indication</th>
<th>Dose, including mg immunoglobulin G (IgG)/kg body weight</th>
<th>Recommended interval before measles or varicella-containing(^1) vaccine administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Botulinum Immune Globulin Intravenous (Human)</td>
<td>1.5 mL/kg (75 mg IgG/kg) IV</td>
<td>6 months</td>
</tr>
<tr>
<td>Tetanus IG (TIG)</td>
<td>250 units (10 mg IgG/kg) IM</td>
<td>3 months</td>
</tr>
<tr>
<td>Hepatitis A IG</td>
<td>0.02 mL/kg (3.3 mg IgG/kg) IM</td>
<td>3 months</td>
</tr>
<tr>
<td>- Contact prophylaxis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- International travel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B IG (HBIG)</td>
<td>0.06 mL/kg (10 mg IgG/kg) IM</td>
<td>3 months</td>
</tr>
<tr>
<td>Rabies IG (RIG)</td>
<td>20 IU/kg (22 mg IgG/kg) IM</td>
<td>4 months</td>
</tr>
<tr>
<td>Varicella IG</td>
<td>125 units/10 kg (60-200 mg IgG/kg) IM, maximum 625 units</td>
<td>5 months</td>
</tr>
<tr>
<td>Measles prophylaxis IG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Standard (i.e., nonimmunocompromised) contact</td>
<td>0.25 mL/kg (40 mg IgG/kg) IM</td>
<td>5 months</td>
</tr>
<tr>
<td>- Immunocompromised contact</td>
<td>0.5 mL/kg (80 mg IgG/kg) IM</td>
<td>6 months</td>
</tr>
<tr>
<td>Blood transfusion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Red blood cells (RBCs), washed</td>
<td>10 mL/kg (negligible IgG/kg) IV</td>
<td>None</td>
</tr>
<tr>
<td>- RBCs, adenine-saline added</td>
<td>10 mL/kg (10 mg IgG/kg) IV</td>
<td>3 months</td>
</tr>
<tr>
<td>- Packed RBCs (hematocrit 65%)(^2)</td>
<td>10 mL/kg (60 mg IgG/kg) IV</td>
<td>6 months</td>
</tr>
<tr>
<td>- Whole blood (hematocrit 35%-50%)(^2)</td>
<td>10 mL/kg (80-100 mg IgG/kg) IV</td>
<td>6 months</td>
</tr>
<tr>
<td>- Plasma/platelet products</td>
<td>10 mL/kg (160 mg IgG/kg) IV</td>
<td>7 months</td>
</tr>
<tr>
<td>Cytomegalovirus IGIV</td>
<td>150 mg/kg maximum</td>
<td>6 months</td>
</tr>
<tr>
<td>IGIV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Replacement therapy for immune deficiencies(^3)</td>
<td>300-400 mg/kg IV</td>
<td>8 months</td>
</tr>
<tr>
<td>- Immune thrombocytopenic purpura treatment</td>
<td>400 mg/kg IV</td>
<td>8 months</td>
</tr>
<tr>
<td>- Immune thrombocytopenic purpura treatment</td>
<td>1,000 mg/kg IV</td>
<td>10 months</td>
</tr>
<tr>
<td>- Kawasaki disease</td>
<td>2 g/kg IV</td>
<td>11 months</td>
</tr>
<tr>
<td>- Postexposure varicella prophylaxis(^4)</td>
<td>400 mg/kg IV</td>
<td>8 months</td>
</tr>
<tr>
<td>Monoclonal antibody to respiratory syncytial virus F protein (Synagis(^\text{TM}))(^5)</td>
<td>15 mg/kg (IM)</td>
<td>None</td>
</tr>
</tbody>
</table>

This table is not intended for determining the correct indications and dosages for using antibody-containing products. Unvaccinated persons might not be fully protected against measles during the entire recommended interval, and additional doses of IG or measles vaccine might be indicated after measles exposure. Concentrations of measles antibody in an IG preparation can vary by manufacturer's lot. Rates of antibody clearance after receipt of an IG preparation also might vary. Recommended intervals are extrapolated from an estimated half-life of 30 days for passively acquired antibody and an observed interference with the immune response to measles vaccine for 5 months after a dose of 80 mg IgG/kg.

1 Does not include zoster vaccine. Zoster vaccine may be given with antibody-containing blood products.

2 Assumes a serum IgG concentration of 16 mg/mL.

3 Measles and varicella vaccinations are recommended for children with asymptomatic or mildly symptomatic human immunodeficiency virus (HIV) infection, but are contraindicated for persons with severe immunosuppression from HIV or any other immunosuppressive disorder.

4 The investigational product VariZIG, similar to licensed VZIG, is a purified human IG preparation made from plasma containing high levels of anti-varicella antibodies (IgG). The interval between VariZIG and varicella vaccine (Var or MMRV) is 5 months.

5 Contains antibody only to respiratory syncytial virus.

Adapted from Table 5, ACIP General Recommendations on Immunization

May 2012
Measles: Infection Prevention and Control for Healthcare Providers

Facilities should develop and implement systems for early detection and management of potentially infectious patients at initial points of entry to the facility, including physician offices and other ambulatory care settings. This may include additional signage or modified respiratory hygiene cough etiquette signage that includes febrile rash illness and suspected or known measles exposure. Consideration should be given to obtaining travel history at the point of triage.

If measles is suspected:

- Healthcare providers should follow airborne precautions and respiratory etiquette in healthcare settings.
- Patients calling for appointments should be screened for symptoms and potential exposure to measles. If measles is suspected, examine the child in the home if possible. If the child must be seen in the clinic, schedule the patient to come in at end of day when other patients are gone. (If needed, consider other practical actions to prevent exposure of potentially susceptible patients in waiting areas, i.e. bring patient in through a back entrance and place immediately in an exam room, or to go out to patient vehicle to evaluate or collect specimens.)
- Patients who are suspected to have measles should immediately put on a mask. If mask cannot be tolerated or the patient is too young, other methods of containment should be considered. For example, place a blanket loosely over the head of the infant or young child when being transported through the facility to a room.
- Promptly place patient into an airborne infection isolation (AII) (negative airflow) room, if available. If not, place patient in a single-patient room with the door closed.
  - Depending on number of air changes per hour, the room may need to remain empty with the door closed for up to two hours after the patient leaves.
  - Refer to Table 1 in the Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Settings, 2005 for recommended air changes per hour required for adequate removal of the contaminated air.
  - If available, use air cleaning technologies such as portable HEPA filtration when an AII room is not available.
- Only allow staff with evidence of immunity to care for patients. Exclude susceptible healthcare personnel from duty from day 5 after first exposure to day 21 after last exposure, regardless of post-exposure vaccine or IG administered.
- Regardless of presumptive immunity status, all healthcare staff entering the room should use respiratory protection consistent with airborne infection control precautions (use of NIOSH
certified N95 or higher level respirator effective in preventing airborne transmission) in addition to following standard precautions.

- If patient requires transfer to another facility, inform the transporting agency (if applicable) and the accepting facility of the suspected infection type.

- Hospitalized patients should be placed in an AII room and under airborne isolation precautions. For patients who are otherwise healthy, airborne precautions are indicated for 4 days after the onset of the rash. If immunocompromised, airborne precautions are indicated for the duration of the illness.

- Hospitalized patients with exposure to a case-patient who do not have presumptive evidence of measles immunity should be vaccinated or offered immune globulin as recommended, and be placed in an AII room on airborne isolation precautions from day 5 after first exposure to day 21 after last exposure, regardless of post-exposure vaccine or IG administered.

- Use standard sterilization and disinfection procedures to clean and disinfect surfaces and equipment that are likely to be contaminated.

**Evidence of measles immunity for Healthcare Personnel:** (Table 3)

- Documentation of vaccination with 2 doses of live measles vaccine given at appropriate age and interval or
- Laboratory evidence of immunity or
- Laboratory confirmation of disease, or
- Born before 1957*

* Per CDC, health care facilities should consider vaccinating healthcare personnel who were born before 1957 and lack laboratory evidence of measles, rubella, or mumps immunity, or appropriate vaccination with live measles vaccine, or laboratory confirmation of disease. Two doses of MMR vaccine administered at the appropriate interval are recommended for measles and mumps immunity.

Resources:


Centers for Disease Control and Prevention. Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Settings, 2005. Centers for Disease Control and Prevention, Atlanta, GA, 2005. Available at: [http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s_cid=rr5417a1_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s_cid=rr5417a1_e)

Joint Committee on Administrative Rules, Administrative Code, State of Illinois. TITLE 77: PUBLIC HEALTH, CHAPTER I: DEPARTMENT OF PUBLIC HEALTH, SUBCHAPTER k: COMMUNICABLE DISEASE
CONTROL AND IMMUNIZATIONS, PART 690 CONTROL OF COMMUNICABLE DISEASES CODE, SECTION 690.520 MEASLES. Retrieved from:


Joint Committee on Administrative Rules, Administrative Code, State of Illinois. TITLE 77: PUBLIC HEALTH, CHAPTER I: DEPARTMENT OF PUBLIC HEALTH, SUBCHAPTER b: HOSPITALS AND AMBULATORY CARE FACILITIES, PART 250 HOSPITAL LICENSING REQUIREMENTS, SECTION 250.1100 INFECTION CONTROL. Retrieved from:

National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Division of Viral Diseases. Measles: For Healthcare Professionals. Centers for Disease Control and Prevention, Atlanta, GA. 2015. Available at http://www.cdc.gov/measles/hcp/

http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm